Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- HIV -- Ignore unavailable to you. Want to Upgrade?

To: DewDiligence_on_SI who wrote (85)	2/21/2009 9:13:03 PM
From: Elroy Jetson	Read Replies (1) \| Respond to of 155

The concept of "improved compliance" with a single tablet has been much promoted by some pharma firms. Apparently you believe them. Yet there is no evidence that patients are more likely to take one large tablet, than three smaller ones, once a day. There is some evidence that compliance is higher with once a day regimens than twice a day regimens. But there's an equal amount of evidence that the downside of a missed dose is greater with a once a day combination than with a twice a day combination. The improved market share for combination tablets has been bought at the expense of profitability. .

To: DewDiligence_on_SI who wrote (85)	2/21/2009 9:29:06 PM
From: Elroy Jetson	Respond to of 155

Combination tablets can also create compliance problems. A frequent example is a patient with a reduced GFR secondary to Viread usage. In this event Atripla needs to be immediately, yet temporarily, replaced with Sustiva and Epivir for several weeks. Since the patient often cannot obtain these medications in a timely manner, this results in non-compliance for a period of time. Some Doctors will simply stop the Atripla, due to the extra complications involved, with a worse outcome for their patient. .